Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
10/06/2026 16:33
BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint June 10 (Reuters) - Alphamab Oncology 9966.HK:
PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)